Smart Immune Doses First Leukemia Patients with ProTcell Therapy SMART101 in ReSET-02 Phase I/II Trial
September 27, 2023
Two Small and medium-sized enterprises (SMEs) and two world-leading institutes from Netherlands and France join forces to propose PRO-THYMUS, a novel groundbreaking solution combining cell and gene therapy to swiftly restore the immune system in patients with acute myeloid leukemia (AML) after blood (hematopoietic) stem cell transplantation (HSCT).
Led by Genewity B.V. (NL), reuniting Institut Imagine (Inserm, AP-HP, Université Paris Cité, FR), Smart Immune (FR) and Leiden University Medical Center (LUMC, NL), the PRO-THYMUS project is laureate of the third EUROSTARS program, which aims to support research and development performing SMEs, fostering their international collaboration capacities.
Please find the full press release below.